Status: current, Defined. Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3773043015 | Substance with vascular endothelial growth factor receptor antagonist mechanism of action (substance) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 3773044014 | Vascular endothelial growth factor receptor antagonist | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 4167520015 | VEGF antagonist | en | Synonym | Active | Case sensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Vascular endothelial growth factor receptor antagonist | Is a | Receptor antagonist | true | Inferred relationship | Some | ||
| Vascular endothelial growth factor receptor antagonist | Has disposition | Vascular endothelial growth factor receptor antagonist | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Sunitinib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Sunitinib malate | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Intravitreal injection of anti-vascular endothelial growth factor | Direct substance | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | 1 |
| Bevacizumab | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Ranibizumab | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pegaptanib sodium | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Sorafenib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pegaptanib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Vandetanib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Axitinib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Sorafenib tosylate | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Cabozantinib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Lenvatinib mesilate | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pazopanib hydrochloride | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Pazopanib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Lenvatinib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Ramucirumab | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Regorafenib | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Aflibercept | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Brolucizumab | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
| Cabozantinib s-malate | Is a | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some |
Reference Sets
Substance foundation reference set
FHIR